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T. HUIZER, J. W. DE JONG, J. A. NELSON, W. CZARNECKI, P. W. SERRUYS, J. J. R. M. BONNIER AND R. TROQUA- 
Urate Production by Human Heart. journal of Molcculor and Cellular Cardiology (1989) 21, 691-695. Xanthine 
oxidoreductase has been demonstrated in the heart of various species. However, its presence in human heart is 
still debated. In the literature, high to undetectable levels have been reported. We studied the arterial-venous 
mate difference across the heart of patients undergoing both routine cardiac catheterization and percutaneous 
transluminal coronary angioplasty. Urate is the end product of the reaction catalysed by xanthine oxidoreduc- 
tase. In 10 patients, studied before angioplasty, the plasma mate level in the great cardiac vein exceeded the 
arterial one by 26 + 10 nmol/ml (P = 0.028). In a further 13 patients, urate production was maximal imme- 
diately after the last of four consecutive occlusions (23 If: 8 nmol/ml, P = 0.018) and concomitant with 
increased coronary sinus hypoxanthine levels. We conclude that xanthine oxidoreductase is probably present in 
the heart of patients, suffering from ischemic heart disease, and responsible for the increase in mate production 
during transient myocardial ischemia. 
KEY WORDS: Xanthine oxidase; Uric acid; Myocardium; Ischemia; Human; Coronary angioplasty. 
Introduction 
Xanthine oxidoreductase activity has been 
demonstrated in the myocardium of a number 
of species (see Schoutsen and De Jong, 1987). 
Limited data are available on the enzyme in 
human heart. Autopsy material indicates high 
xanthine oxidase activity (Krenitsky et al., 
1974; Wajner and Harkness, 1988). Histo- 
chemical techniques have shown large 
amounts of the enzyme in human heart endo- 
thelium (Jarasch et al., 1986). On the other 
hand, several authors have reported very low 
to undetectable xanthine oxidoreductase 
activity in human heart (Ramboer, 1969; 
Eddy et al., 1987; Muxfeldt and Schaper, 
1987) Preliminary observations assessing 
cardiac urate production in patients during 
pacing stress test at the University of Alabama 
~Nelson et al., 1977) and in patients during 
coronary angiography in the National Insti- 
tute of Cardiology, Warsaw (Czarnecki, 
1988) have suggested that the human heart 
may be capable of urate production. We 
present evidence which shows that the human 
heart can produce significant amounts of 
urate. This observation suggests that a cardiac 
xanthine oxidoreductase is active in patients 
with ischemic heart disease. 
Methods 
Patients 
Two studies were performed in patients, 
catheterized for percutaneous transluminal 
coronary angioplasty (PTCA). In 10 patients 
the urate concentrations of arterial and great 
cardiac vein plasma, obtained before PTCA, 
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TABLE 1. Clinical characteristics of the study 
groups 
Variable 
Group 1 Group 2 
n= 10 n= 13 
Age (year), average 
range 
Gender (male/female) 
CCS grade 
Average severity 
of stenosis (%) 
before PTCA 
after PTCA 
58 58 
49 to 66 43 to 72 
713 1013 
III to IV II to IV 
78 79 
44 37 
CCS = Canadian Cardiovascular Society 
were assayed retrospectively (Group 1). Sub- 
sequently, in a prospective study (Group 2, 13 
patients), urate and hypoxanthine concentra- 
tions were measured in arterial and coronary 
sinus plasma before, during and after angio- 
plasty. In both studies, arterial blood was 
taken from the femoral artery. Great cardiac 
vein blood was sampled via the distal opening 
of a Webster flow catheter (Group 1) and 
coronary sinus blood via a diagnostic catheter 
(Group 2). All patients had a proximal sten- 
osis < 1 cm from the origin of the left anterior 
descending artery and no collateral filling to 
the region supplied by the artery, seen at 
angiography. Amipaque or Isopaque contrast 
agents (Nyegaard, Oslo, Norway) were used 
for angiography. In all patients, vasoactive 
substances, except short-lasting nitrates, were 
discontinued at least 12 h before the study. 
The clinical characteristics are listed in 
Table 1. 
Assays 
To prepare plasma, blood was mixed in a 
heparinized tube with an equal volume of ice- 
cold 154 mM NaCl, containing 20 PM dipyri- 
damole (Boehringer, Ingelheim, GFR) and 
10 PM erythro-9- (2-hydroxy-3-nonyl) adenine 
(Wellcome, London, UK). These drugs were 
used to inhibit adenosine uptake and break- 
down (Ontyd and Schrader, 1984; Edlund et 
al., 1985). The plasma was kept at -80°C. 
Deproteinization was carried out with an 
equal volume of 8% HC104 (w/v) and the 
supernatant fraction neutralized with 2 M 
KOH/l M K,CO, . HPLC-determination of 
urate and hypoxanthine concentrations in the 
plasma extract were performed on a PBonda- 
pak CIS column. A 100 ~1 sample was eluted 
with a mixture of CH30H (100 ml) and 
KH,P04 (10 g/l, 1000 ml), pH 5-7, at a flow 
a 
I  !  
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FIGURE 1. High-performance liquid chromatography of plasma extract. Urate was detected at 295 nm, hypo- 
xanthine at 254 nm. The contrast agent used showed up in the chromatogram, but did not interfere with the peaks of 
interest. 
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TABLE 2. Arterial and venous urate levels before, immediately after four dilations, and during recovery 
Before PTCA After 1st dilation After 2nd dilation After 3rd dilation After 4th dilation Recovery 
Patient 
no. ART CS ART CS ART CS ART CS ART CS ART CS 
I 217 211 214 217 211 217 218 216 212 217 215 ‘IR 
2 236 216 224 184 216 195 213 207 213 200 202 196 
3 224 229 223 220 218 215 218 219 217 217 215 ‘211 
4 279 291 280 290 279 281 236 292 245 284 262 “82 
5 242 254 231 266 239 257 244 260 200 266 230 253 
6 216 224 219 221 208 216 211 218 209 216 202 206 
7 252 261 260 252 258 258 244 262 253 245 244 240 
8 449 495 457 481 481 478 455 480 469 512 462 469 
9 196 188 185 181 179 182 177 178 175 174 168 173 
10 230 242 218 214 201 207 197 209 191 204 187 197 
II 292 278 264 268 271 299 266 281 272 283 239 264 
12 239 207 241 191 234 224 220 230 184 238 225 221 
13 192 268 208 244 253 208 253 279 174 251 226 23’4 
MeUl 251 259 248 248 250 249 242 256 232 254 237 244 
S.E.M. 18 21 19 22 21 21 19 21 21 23 20 21 
.ART = arterial; CS = coronary sinus. Data are in nmol/ml 
rate of0.6 ml/min. The column was equipped 
with a LC-18 guard-column (Supelco, Belle- 
fonte, PA). The Waters-HPLC equipment 
consisted of: WISP 7 10B cooled autosampler, 
Model 6000A pump, Model 490 multi wave- 
length detector, and Model 840 computer. 
Peaks were identified by retention times, 
internal standards and enzyme shifts. The 
optimal wavelengths for urate and hypo- 
xanthine detection proved to be 295 and 254 
nm as at these levels adsorption was maximal 
and disturbance by other materials minimal 
(Fig. 1). Sample preparation and assay were 
based on earlier work (Harmsen et al., 1981). 
In 27 arterial and venous plasma samples of 
Group 2, urate was also assayed spectrophoto- 
metrically with uricase according to Scheibe et 
al. ( 1974). Enzyme was provided by Boehr- 
inger (Mannheim, GFR). Comparison of the 
data obtained with both methods showed that 
they correlated closely. 
Data presented were analysed with 
Student’s t-test for paired variates, or, where 
appropriate with two-way analysis of 
variance. A P value of <0.05 was considered 
as significant. The correlation test was done 
according to Bland and Altman (1986). 
Results 
In the preliminary studies, mentioned in the 
Introduction, hearts produced urate. In the 
American study, the arterial and venous 
blood urate levels were 59 + 20 and 120 & 23 
nmol/ml, resp. (n = 7, P = 0.003). In the 
Polish study, these values were 96 + 15 and 
145 + 25 nmol/ml resp. (rz = 6, P = 0.028). 
In Group 1, all patients had an isolated 
proximal left anterior descending artery sten- 
osis and angina pectoris. In this group the 
arterial urate concentration was significantly 
lower than the coronary venous one 
(2 16 & 17 and 242 + 17 nmol/ml) ; a differ- 
ence of 26 nmol/ml (P = 0.028). In seven out 
of 10 patients, the heart produced urate. 
In a comparable patient population 
(Group 2, see Table 2), plasma urate concen- 
trations were similar to those of Group 1, but 
the arterio-venous difference before coronary 
angioplasty was relatively small. Consequent- 
ly we were unable to demonstrate significant 
urate production before coronary angioplasty. 
Analysis of data showed a significant increase 
in urate production during balloon inflations 
(F = 2.85; P < 0.05). After the third and 
fourth inflations, venous urate levels were sig- 
nificantly higher than arterial ones (Fig. 2). 
They differed 14 nmol/ml (P = 0.009) and 23 
nmol/ml (P = 0.018), resp. Even after 15 min 
of recovery, urate production was still signifi- 
cant. The difference was 7 nmol/ml 
(P = 0.033). 
In the latter study we also measured the 
arterial and coronary sinus hypoxanthine 
levels with HPLC. The arterial hypoxanthine 
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FIGURE 2. Urate production by the heart of 13 
patients with single left anterior descending coronary 
artery stenosis, before coronary angioplasty (pm), after 
each balloon deflation (dilation one to four) and after 15 
min of recovery (post). Mean coronary venous-arterial 
values are given with 1 S.E.M. Significant urate production 
was found immediately after the last two dilations, and 
during recovery. 
plasma concentration slightly exceeded the 
venous one before angioplasty (0.58 & 0.07 
and 0.42 + 0.07 nmol/ml, respectively, 
P = 0.015). Immediately following PTCA 
these values were 0.32 + 0.06 and 1.28 + 0.19 
nmol/ml, respectively, P < 0.001 (average of 
four attempts). Thus cardiac uptake turned 
into production. Fifteen minutes after angio- 
plasty arterial plasma hypoxanthine levels 
were not different from the venous ones. 
Discussion 
Xanthine oxidoreductase activity is detect- 
able in the heart of a number of species (for 
reviews, see Schoutsen and De Jong, 1987 ; 
Downey et al., 1988). In pig heart it seems to 
be absent (Podzuweit et al., 1986; Muxfeldt 
and Schaper, 1987). In rabbit heart both 
Schoutsen et al. (1983) and Chambers et al. 
(1985) were unable to demonstrate the 
enzyme, but Wajner and Harness ( 1988) 
measured high activity. The literature on 
xanthine oxidoreductase in human heart is 
also conflicting. The reports vary from high 
(Krenitsky et al., 1974; Jarasch et al., 1986; 
Wajner and Harness, 1988) to (very) low 
levels (Watts et al., 1965; Ramboer, 1969; 
Eddy et al., 1987; Muxfeldt and Schaper, 
1987). We want to emphasize that in these 
reports the number of samples assayed was 
often very small. Muxfeldt and Schaper 
119871 found verv low amounts of xanthine 
oxidoreductase in the two human heart bi- 
opsies studied. Krenitsky et al. (1974) reported 
data on one autopsy sample. These authors 
observed enzyme activity with ferricyanide as 
the electron acceptor but did not use NAD or 
oxygen as the cosubstrate. Allopurinol inhib- 
ited the activity. Eddy et al. (1987) could not 
demonstrate xanthine oxidoreductase in 
human ventricular tissue. Supposedly the four 
biopsies studied were not taken from ischemic 
hearts. 
A possible explanation for the discrepancies 
in activity found could be a difference in 
quality of the hearts examined. Our data indi- 
cate that the enzyme could be active in the 
human heart in viva. We cannot exclude that 
the urate production measured originated 
from xanthine oxidoreductase activity in 
polymorphonuclear neutrophils, adhering to 
areas of the coronary endothelium that are 
injured by the balloon during inflation. 
In the American and Polish studies, men- 
tioned before, blood was deproteinized with 
HC104 which causes a partial loss during 
sample clean-up. Never the less the arterio- 
venous differences in urate were significant. 
Moreover, they suggested that patients with a 
more severe ischemic heart disease produced 
the highest amounts of urate. In the American 
study, patients experiencing pain during a 
pacing stress test released lactate and showed 
the highest urate production. Czarnecki 
(1988) observed that patients with a history of 
subendocardial infarction produced high 
amounts of urate whereas patients with 
normal myocardium or extensive myocardial 
damage produced less. Our present results 
support this idea. Group 1, which comprised 
patients with CCS grades III and IV, showed 
significant urate production before PTCA. 
Group 2, in which four out of 13 patients were 
CCS grade II, only started to produce signifi- 
cant amounts of urate after several dilations. 
After each of the angioplasty attempts, venous 
plasma hypoxanthine [the relatively stable 
substrate for xanthine oxidoreductase 
(Harkness, 1988)] increased fourfold. The 
data suggest that ischemic myocardium at risk 
of infarction produces urate. 
Patients of Group 1, all with a proximal 
stenosis of the left anterior descending coro- 
nary artery produced urate (Table 1). It is 
likelv that this urate production was partly 
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due to endothelial damage, caused by inser- 
tion of the guide wire and the balloon cathe- 
ter. In Group 2 urate production, which was 
not significant before PTCA, became obvious 
after repetitive angioplasty attempts (Fig. 2). 
Presumably, this is due to cardiac ATP break- 
down, with a concomitant rise in hypo- 
xanthine as a result of myocardial ischemia 
due to coronary occlusion by balloon inflation 
(sre also Serruys et al., 1989). Hypoxanthine 
serves as a substrate for xanthine oxidoreduc- 
tase. We suggest that the human heart ma) 
contain active xanthine oxidoreductase. 
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